“There’s not enough money in the average person’s pocket to take care of the increases in premiums companies would have to charge,” said Dr. Richard Snyder, senior vice president and chief medical officer for Independence Blue Cross.
The sheer number of genetic tests has exploded in the past decade or so. There are now thousands of different testable genetic disorders. In fact, demand for genetic tests has been strong since 2013.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
“Our ability to sequence genes has gotten ahead of our ability to know what it means,” said Eric P. Winer, the director of the breast oncology program at Harvard’s Dana-Farber Cancer Institute.
The test provides fitness regimens, diet and supplement options, skin and dental care recommendations as well as mental health input.
"Soon we're going to be in Walgreens," 23andMe Chief Scientific Officer Richard Scheller reportedly said at a forum at the University of California, San Francisco. "You just buy one."
Genetic testing can play a critical role in helping potential parents understand their options if they are carriers for a wide array of genetic disorders, such as cystic fibrosis.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Tests are available in all Rite Aid stores other than those in New York state, the pharmacy chain said.
Following the shutdown by the FDA, 23andMe is back in business and reportedly took advantage of its two-year hiatus.
The health insurer saved more than $650,000 in the first year by individualizing interventions for employees at high risk of developing metabolic syndrome, according to peer-reviewed study.
Also, a sixth Obamacare co-op had failed, Bristol-Myers Squibb inks a $1.7 billion cancer licensing deal, and learn how Jeb Bush's healthcare reform would impact health IT.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
23andMe keeps moving forward with a massive round of fundraising.
Eric Topol proves the relevance of his "prewomb to tomb" mantra on individualized medicine by sharing his own genetic information - he's a carrier for two rare diseases. Topol spoke with MedCity News to advocate carrier screening for prospective parents.
A ProPublica report centered on patient safety and physician performance reveals surgical complication rates, a research study shows how genetic test for fetus could identify whether mom has cancer.
Here’s another thing to file in the “Europe’s a better place to launch devices and diagnostics” bucket: Controversial DNA testmaker 23andMe just made a smooth entrance into the United Kingdom market. The Food and Drug Administration made the Google-backed company pull its health-related test – which tells consumers whether they’re genetically prone to certain diseases – […]
A lot of the discussion around personalized medicine focuses on surviving cancer or other scary illnesses. In my experience, people need as much help with dying as they do with surviving. Any change – more hospice programs, better pain management, more informed patients, more honest doctors – that can make it easier for elderly or […]